Waiting For FDA: Federal Courts Debate Stays Of 'Natural' Class Actions
This article was originally published in The Rose Sheet
Executive Summary
Mayer Brown attorney Dale Giali discusses the "natural" litigation landscape, where litigants increasingly are sparring over the appropriateness of stays in light of FDA's comment-gathering initiative launched in 2015.
You may also be interested in...
MoCRA-Required Recordkeeping, Reporting Now ‘Fair Game’ For Litigants – Crowell & Moring
Cosmetic product manufacturers can expect the plaintiffs’ bar to leverage new record-keeping, GMP and other provisions of the Modernization of Cosmetic Regulations Act to bring or advance litigation, Crowell & Moring attorneys say. They note some defensive tactics that could prove effective.
Dr. Dennis Gross Skincare Could Be Headed To Trial Over Alleged ‘Fake Collagen Cosmetic Products’
After California’s Central District denied Dr. Dennis Gross Skincare’s motion to dismiss in November 2020 and granted class certification to plaintiffs in April 2023, the New York-based defendant seems intent on continuing the fight. DDG has argued that “collagen amino acids” and “vegan” disclosures on its C + Collagen product labels sufficiently convey to consumers that animal byproducts are not present in the formulas.
GMO Evolution Creates Challenges For ‘Clean Label’ Supplement Marketers
Supplement and food firms should "check to see if any ingredients they use may be affected or potentially contaminated by genetically engineered bio-synthesized ingredients,” said Jim Thomas, scientist and co-founder of ETC Group. Biotechnologies have emerged to yield ingredients for clean label products with organisms raised in ecosystems developed from processes that involve genetic engineering.